Two challenges,
one breakthrough
Our deep understanding of two historical challenges of oligonucleotides became the foundation of our platform.
Industry design challenge
Industry design challenge
Nucleic acids are not comprised of just one molecule, but rather
a mixture of many hundreds of thousands of molecules.
While most medicines are required to be characterized with their
chirality, previously the industry did not have the means or methods to
control chirality in nucleic acids ... neither by separating the molecules
nor by manufacturing molecules with a set chirality.
Wave identified this need as the key to controlling pharmacology.
Industry manufacturing challenge
Industry manufacturing challenge
To unlock the concept of chiral design, a proprietary process is
needed to manufacture stereopure oligonucleotides efficiently,
reliably and economically.
Wave recognized this challenge and developed key principles to
better understand chiral impacts as well as how to manufacture these
molecules at a cost equivalent to traditional stereorandom molecules.
The extent of this research includes an evaluation of
over 10,000 oligonucleotides.
;)
;)
){kind=logo}
Industry design challenge
Industry design challenge
Nucleic acids are not comprised of just one molecule, but rather
a mixture of many hundreds of thousands of molecules.
While most medicines are required to be characterized with their
chirality, previously the industry did not have the means or methods to
control chirality in nucleic acids ... neither by separating the molecules
nor by manufacturing molecules with a set chirality.
Wave identified this need as the key to controlling pharmacology.
Industry manufacturing challenge
Industry manufacturing challenge
To unlock the concept of chiral design, a proprietary process is
needed to manufacture stereopure oligonucleotides efficiently,
reliably and economically.
Wave recognized this challenge and developed key principles to
better understand chiral impacts as well as how to manufacture these
molecules at a cost equivalent to traditional stereorandom molecules.
The extent of this research includes an evaluation of
over 10,000 oligonucleotides.
The breakthrough: Our proprietary platform
These two foundational understandings and the subsequent seminal work by the Wave scientific team has enabled a deep understanding of the principles of chiral design that can be applied across multiple modalities.
Rather than separating the mixtures, Wave’s proprietary approach enables the creation of stereopure oligonucleotides: building amidites, setting optimal chirality at each linkage and manufacturing them consistently. We are able to design and optimize nucleic acids for several pharmacologic properties, including safety and potency, and manufacture them at scale.